High TIRADS may signal cancer despite benign cytology
-
By
-
Andrea Surnit
-
October 30, 2026
-
3 min
By
Andrea Surnit
October 30, 2026
Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.
September 1, 2026
Researchers assessed preferred hot drink temperature and consumption frequency across 2 large UK cohorts.
September 16, 2026
Five reproducible MASLD subtypes showed distinct genetic profiles and patterns of metabolic comorbidity and disease progression.
September 10, 2026